Data compiled by Redley Lamar · ChainSifter Intelligence
1Suppliers
10Customers
1Debt Items
16Related Chains
Source-Backed Evidence Depth
Arcturus Therapeutics Holdings Inc. (ARCT) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
13Total relationships
1Distinct source URLs
5High confidence
0.748Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Reciprocal relationship from FDMT graph: val of a product or impose restrictions on its distribution, such as in the form of a REMS. The failure to obtain timely regulatory approval of product candid…
Arcturus Therapeutics Holdings Inc. Customers
Ticker
Name
Confidence
Evidence
CSL-SEQIRUS
CSL-SEQIRUS
92%
In evaluating the CSL Collaboration Agreement in accordance with ASC 606, the Company concluded that CSL Seqirus is a customer.
BARDA
BARDA
90%
The Company determined that the BARDA Contract is not in the scope of ASC 808 or ASC 606. Applying International Accounting Standards No. 20 (IAS 20), Accounting for Government Grants and Disclosure …
GATES-FOUNDATION
GATES-FOUNDATION
85%
The Company recognized $ 0.6 million of grant revenue related to cost reimbursement under two grants awarded by the Gates Foundation.
ts with pharmaceutical and biotechnology partners and government agencies that may contain upfront payments, license fees for research and development arrangements, research and development funding, …
Reciprocal relationship from CSLLY graph: Reciprocal relationship from ARCT graph: Reciprocal relationship from CSLLY graph: Reciprocal relationship from ARCT graph: ts with pharmaceutical and biotec…
CSL-SEQIRUS-INC
CSL-SEQIRUS-INC
62%
ts with pharmaceutical and biotechnology partners and government agencies that may contain upfront payments, license fees for research and development arrangements, research and development funding, …
GENERAL-FINANCIAL-RESOURCES
GENERAL-FINANCIAL-RESOURCES
62%
ur proprietary self-amplifying messenger RNA-based vaccine platform. The BARDA Contract is to support our non-clinical and pre-clinical development, early-stage clinical development through Phase 1, …
IN-CSL-LIMITED
IN-CSL-LIMITED
62%
ficer, who reviews and evaluates consolidated net loss for purposes of assessing performance, making operating decisions, allocating resources, and planning and forecasting for future periods. The CO…
MEIJI-HOLDINGS-CO-LTD
MEIJI-HOLDINGS-CO-LTD
62%
ficer, who reviews and evaluates consolidated net loss for purposes of assessing performance, making operating decisions, allocating resources, and planning and forecasting for future periods. The CO…
WELLS-FARGO-SECURITIES-LLC
WELLS-FARGO-SECURITIES-LLC
62%
d to such product candidates, (iii) provisions of the CSL Collaboration Agreement related to specific royalty payments, (iv) provisions of the CSL Collaboration Agreement related to distributors, and…
Arcturus Therapeutics Holdings Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
ARCT-DEBT
Debt stack $75.7M
90%
Market cache reports total debt of $75.7M.
Arcturus Therapeutics Holdings Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Arcturus Therapeutics Holdings Inc..
Arcturus Therapeutics Holdings Inc. Ownership
Holder
Name
Confidence
Evidence
ARCT-OWNER-FEDERATED-HERMES-INC
FEDERATED HERMES, INC.
90%
13F overlay lists FEDERATED HERMES, INC. as top holder; 127 tracked holders.
Arcturus Therapeutics Holdings Inc. Extended Supply Chain Network
